
Yun Wang
- Senior consultant; MD, PhD
- +47 22 93 47 71
Dr. Wang received her Medical Degree from Dalian Medical University in China and completed residency training at the second affiliated hospital of Dalian Medical University in China. She got a scholarship from Norwegian Research Council in1999 and got PhD from the Faculty of medicine, Oslo University in Norway 2005 and Norwegian authorization as medical doctor on March 2007. She worked at the department of Gynecology and Obstetrics in Oslo University hospital- The national hospital from 2007 to 2010 and has since worked at the department of Gynecologic Oncology at the Norwegian Radium Hospital where she provides surgical and medical treatment for women with gynecologic malignancies. Dr. Wang heads the vulvar cancer at the Radium Hospital. Her principal area of clinical practice is cytoreductive operation for advanced ovarian cancer, advanced minimal invasive surgery for gynecologic cancer and advanced procedures with reconstruction of vulva for vulvar cancer.
Publications in chinese
Wang Y, Chang D-An. Histochemical study of carbohydrate of human endosalphinx. Reproduction and Contraception, 1994; 14(2): 101 - 107 (In Chinese)
Wang Y, Tang HJ. Clinical analysis of 66 cases of persistent occiput posterior position. Journal of Postgraduates of Medicine 1998; 21: 82 -83 (In Chinese)
Wang Y, Meng YQ, Wu BT, Zhao CHY. The study of IL-8 concentrations in peritoneal fluid of women with endometriosis. Chinese Journal of Obstetrics and Gynecology 1998; 33(10): 630 - 635 (In Chinese)
Wang Y, Tang HJ, Wu BT, Gao WT, Zhang X, Gao XSH. Laboratorial study of Chinese herb "CuShengTang" on promoting the cervical ripening of the pregnant mice. Chinese Journal of traditional medical science and technology,1999; 2: 75 - 80 (In Chinese)
Book In Chinese
Editor: Wang X, Ya Zh, Wang Y Compulsory reader of Climacteric Syndrome. Shen Yang Publishing Company, 1998.
Publications 2021
Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma
J Clin Med, 10 (14)
DOI 10.3390/jcm10143094, PubMed 34300260
Publications 2018
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
Int J Gynecol Cancer, 28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455
Publications 2014
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
BMC Cancer, 14, 937
DOI 10.1186/1471-2407-14-937, PubMed 25494701
Publications 2013
High levels of genomic aberrations in serous ovarian cancers are associated with better survival
PLoS One, 8 (1), e54356
DOI 10.1371/journal.pone.0054356, PubMed 23372714
Publications 2011
A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation
Biol Blood Marrow Transplant, 18 (5), 747-53
DOI 10.1016/j.bbmt.2011.09.012, PubMed 21963879
Effect of pregestational maternal, obstetric and perinatal factors on neonatal outcome in extreme prematurity
Arch Gynecol Obstet, 284 (6), 1381-7
DOI 10.1007/s00404-011-1870-5, PubMed 21387086
Publications 2010
The impact of advanced maternal age and parity on obstetric and perinatal outcomes in singleton gestations
Arch Gynecol Obstet, 284 (1), 31-7
DOI 10.1007/s00404-010-1587-x, PubMed 20632182
Publications 2009
Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
Nucleic Acids Res, 37 (12), e89
DOI 10.1093/nar/gkp413, PubMed 19474344
Publications 2007
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients
Ann Oncol, 18 (5), 964-6
DOI 10.1093/annonc/mdm134, PubMed 17488735
Publications 2006
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
PLoS Med, 3 (3), e47
DOI 10.1371/journal.pmed.0030047, PubMed 16417408
Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (vol 24, pg 21, 2004)
Hum. Mutat., 27 (2), 209-210
DOI 10.1002/humu.20298
Publications 2005
High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas
Genes Chromosomes Cancer, 42 (3), 228-37
DOI 10.1002/gcc.20128, PubMed 15578687
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
BMC Cancer, 5, 134
DOI 10.1186/1471-2407-5-134, PubMed 16229746
PIK3CA mutations in advanced ovarian carcinomas
Hum Mutat, 25 (3), 322
DOI 10.1002/humu.9316, PubMed 15712344
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
Am J Clin Pathol, 124 (3), 392-401
DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507
Publications 2004
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Br J Cancer, 90 (3), 678-85
DOI 10.1038/sj.bjc.6601537, PubMed 14760384
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
DOI 10.1002/humu.20055, PubMed 15221786